About Us

Contact Us

Home About Us Product News Order Career Contact


           APIs&Intermediates Chemicals of Shanghai APIs Chemical Co., Ltd 


Product Indentification

Name:   CP 690550
Synonyms:   3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
CAS Registry Number:   477600-75-2
Molecular Formula:   C16H20N6O
Molecular Weight:    312.37
Molecular Structure:    


                   In stock! Bulk!





                   Storage: 4 deg C



                   For Research Use Only



                  Inquiry (H1NMR,HPLC,LC-MS)



Related  JAK inhibitors:


                             LY 2784544|1229236-86-5                                                    Ruxolitinib|941678-49-5 


                            1056634-68-4|CYT387                                                           CP 690550|477600-75-2


                            AZ960|905586-69-8                                                              AT9283|896466-04-9


                            AG 490|133550-30-8                                                             INCB 018424|1092939-17-7


                           111358-88-4|Lestaurtinib                                                935666-88-9|AZD-1480





Related pages:

     Search CP 690550 in google
     Search CAS 477600-75-2  in google
     Search C16H20N6O in google


Related info:


        Tofacitinib (formerly tasocitinib, CP-690550) is a drug being investigated by Pfizer for the treatment of rheumatoid arthritis (RA), psoriasis, inflammatory bowel disease, and other immunological diseases, as well as for the prevention of organ transplant rejection. It is an inhibitor of the enzyme Janus kinase 3 (JAK3), which means that it interferes with the JAK-STAT signaling pathway, which transmits extracellular information into the cell nucleus, influencing DNA transcription.

Recently it has been shown in a murine model of established arthritis, tofacitinib rapidly improved disease by inhibiting the production of inflammatory mediators and suppressing STAT1-dependent genes in joint tissue. This efficacy in this disease model correlated with the inhibition of both JAK1 and 3 signaling pathways, suggesting that tofacitinib may exert therapeutic benefit via pathways that are not exclusive to inhibition of JAK3.




Home About Us Product News Order Career Contact
 Copyright @ 2010-2011 APIs All rights reserved